



18th International Myeloma Workshop

SEPTEMBER 8-11, VIENNA AUSTRIA



Wednesday, September 8th

09:00-10:00

OPENING SESSION

Opening Ceremonies and Welcome to IMW18
IMS President Address

Organizers of 18th IMW
Nikhil Munshi

10:00-11:15

PLENARY SESSIONS

Precursor Conditions

Session Chairs: Mario Boccadoro/Sigurdur Kristinsson

Genomic evolution - germinal B cell to MGUS/SMM/MM	Brian Walker
Role of the immune Microenvironment in the journey to MGUS/SMM/MM	Madhav Dhodapkar
Molecular Timing of Initiation	Niels Weinhold
Risk factors for MGUS/SMM progression	Vincent Rajkumar
Management of Smoldering Myeloma	Marivi Mateos
Should we screen for precursor conditions?	Irene Ghobrial

11:15-12:30

Molecular dissection of myeloma

Session Chairs: Leif Bergsagel/Masood Shamma

Clonal diversity in Myeloma	Mehmet Samur
Transcriptome	Jill Corre
Epigenomic	Wee Joo Chng
Microbiome	Leif Bergsagel
Proteomics	Arun Wiita
Metabolomics	Rafael Fonseca

12:30-13:30

EXPOSITION AND LUNCH

13:30-14:30

PLENARY SESSION

Multiple Myeloma Diagnosis

Session Chairs: Sonja Zweegman/P. Joy Ho

Diagnostic criteria and work-up in 2021	Shaji Kumar
How should we define standard and high risk MM in 2022?	Herve Avet-Loiseau
Role of imaging in diagnosis and response assessment	Elena Zamagni
Circulating tumor cells and tumor DNA for response assessment	Bruno Paiva
Mass-spec to monitor the treatment response	Dave Murray
Assessment of patient frailty and functional status	Alessandra Larocca

14:30-15:15

IMS AWARDS

Bart Barlogie/Ken Anderson Young Investigator Award Presentation
Waldenstrom Award Presentation and Lecture

15:15-15:45	EXPOSITION AND BREAK	
15:45-16:45	INDUSTRY SYMPOSIUM SUPPORTED BY SANOFI	
	Welcome and Introduction	Tom Martin (Chair)
	A critical part of the puzzle: Should MRD guide adaptive treatment?	Fredrik Schjesvold
	Assembling the evidence: The pros and cons of MRD as a surrogate endpoint	Tom Martin
	The role of MRD negativity in HR NDMM: a new piece to overcoming poor prognosis?	Martin Kaiser
	Panel discussion and concluding remarks	All faculty
16:45-17:45	HOT TOPICS IN MYELOMA	
	Regulatory considerations	
	<i>Session Moderators: Nikhil Munshi/Jesús San-Miguel</i>	
	FDA perspective	Nicole Gormley
	EMA perspective	TBC
	I square effort updates and future directions	Brian Durie
17:45-19:15	WELCOME RECEPTION IN EXPOSITION AREA	

Thursday, September 9th

08:00-09:00	MEET THE EXPERTS	
	Extramedullary disease	Cyrille Touzeau
	Plasma cell leukemia	Artur Jurczyszyn/Ravi Vij
	Management of Monoclonal gammopathy of renal significance	Javier de la Rubia/ Moshe Gatt
	Management of Monoclonal gammopathy of clinical significance	Laura Rosiñol/ Ajay Nooka
	Special forms of MM: macrofocal, non-secretory MM	Stathis Kastiris/ Jacob Laubach
	Management of LC Amyloidosis	Vaishali Santhorawala/ Eli Muchtar
	Management of Waldenström's Macroglobulinemia	Ramón García-Sanz/ Prashant Kapoor
	Management of POEMS	Angela Dispenzieri/ Anita D'Souza
	Allogeneic Stem Cell Transplantation in MM	Amrita Krishnan/ Charlotte Pawlyn
08:00-09:00	CAREER DEVELOPMENT WORKSHOP	
	Writing successful grants	Suzanne Lentzsch/ Diane Jelinek

09:00-09:30

OPENING SESSION

Novel therapies for myeloma

Kenneth Anderson

09:30-10:30

PLENARY SESSION

Newly diagnosed Multiple Myeloma: Current Treatment Approaches

Session Chairs: David Siegel

Treatment of Newly Diagnosed Myeloma Transplant Eligible: what is the optimal induction?	Philippe Moreau
ASCT in NDMM transplant eligible	Michele Cavo
Consolidation Strategies for MM	Pieter Sonneveld
Maintenance Strategies for MM	Hartmut Goldschmidt
Treatment of Newly Diagnosed Myeloma Non-Transplant Eligible	Theirry Facon

10:30-11:45

ORAL ABSTRACT SESSIONS

Session Chairs: Lugui Qiu/Ed Stadtmauer

Overall Survival and Progression-free Survival by Treatment Duration With Daratumumab + Lenalidomide/ Dexamethasone in Transplant-ineligible Newly Diagnosed Multiple Myeloma: Phase 3 MAIA Study	Philippe Moreau
Daratumumab improves depth of response and progression free survival in transplant-ineligible, high-risk, newly diagnosed multiple myeloma (NDMM)	Andrzej Jakubowiak
CARDAMON:Carfilzomib (K) maintenance following Autologous Stem Cell Transplant (ASCT) or carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation for newly diagnosed (NDTE) multiple myeloma (MM)	Rakesh Popat
Carfilzomib-Based Induction/Consolidation With or Without Autologous Transplant and Lenalidomide (R) or Carfilzomib-Lenalidomide (KR) Maintenance: Efficacy in High-Risk Patients of the FORTE study	Roberto Mina
Update of Safety and Efficacy of Isatuximab Short-Duration Fixed-Volume Infusion Plus Bortezomib, Lenalidomide, and Dexamethasone Combined Therapy for NDMM Ineligible/With No Immediate Intent for ASCT	Enrique O'oro

Session Chairs: Paola Neri/Dharminder Chauhan/Niklas Zojer

A novel algorithm to identify, characterize and define the prognostic impact of complex catastrophic events in Multiple Myeloma	Vincenza Solli
Single-cell multiomic analysis identifies regulatory programs in relapsed/refractory multiple myeloma	Alexandra Poos
Identification of High-Risk Multiple Myeloma with a Plasma Cell Leukemia-Like Transcriptomic Profile	Davine Hofste op Bruinink
Genome-Wide CRISPR interference Screen Identifies RNA Regulator of Lipogenesis (RROL) as a Leading LncRNA Dependency in Multiple Myeloma	Eugenio Morelli

Gain(1q) promotes mitochondrial oxidative phosphorylation and suppresses interferon response and tumor immunity in multiple myeloma and other human cancers	Rodger Tiedemann
Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single cell level	Yuting Yan

PLENARY SESSION

11:45-12:45

Management of relapsed/refractory MM patients

Session Chairs: Meral Beksac/Gösta Gahrton

Approach to first relapse	Meletios-Athanassios Dimopoulos
Management of triple refractory patients	Bob Orłowski
Role of immunotherapies for relapsed MM, when and which?	Saad Usmani
Personalized treatment of relapsed MM: genomics?	Marc Raab

12:45-13:45

EXPOSITION AND LUNCH

13:45-15:15

INDUSTRY SYMPOSIUM SUPPORTED BY JANSSEN

The role of non-cellular modern therapeutics in the treatment of myeloma

Welcome and introduction	Ajai Chari (Chair)
Evolving treatment strategies in multiply-relapsed multiple myeloma	Gordon Cook
Clinical results from BCMA targeted T-cell redirectors	Niels van de Donk
Early clinical results of alternative targets for bispecifics and next generation T-cell redirectors	Ajai Chari
Implications for clinical practice with these new agents	Hareth Nahi
Panel discussion and concluding remarks	All faculty

15:15-16:30

ORAL ABSTRACT SESSIONS

Session Chairs: Natalie Callander/Merav Leiba

Depth of response and MRD in newly diagnosed ultra high-risk myeloma and plasma cell leukemia treated with Dara-CVRd and V-MEL ASCT: results of the molecularly stratified UK OPTIMUM/MUKnine trial	Martin Kaiser
Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)	Sagar Lonial
Newly diagnosed Multiple Myeloma patients with high levels of circulating tumor cells are distinguished by increased bone marrow plasma cell proliferation	A. Cathelijne Fokkema
Minimal residual disease following autologous stem cell transplant for myeloma patients in the Myeloma XI trial: prognostic significance and the impact of lenalidomide maintenance and molecular risk	Ruth De Tute

Treatment pathways for patients with multiple myeloma: a real-life study based on the French National Claim database from 2014 to 2019	Aurore Perrot
--	---------------

Session Chairs: Enrique Ochoa/Annemeik Brojil

Attenuation of T cell cytotoxicity mediated by CD200 expression on multiple myeloma cells	Pooja Shah
A BCL2L1 armoured BCMA-targeting CAR T cells to overcome exhaustion and enhance persistence in multiple myeloma	Nizar Bahlis
CRISPR screens with single-cell transcriptome readout reveal potential mechanisms of response to natural killer cell treatment in multiple myeloma	Sara Gandolfi
The Role of Checkpoint inhibitor PD-1H/VISTA in Multiple Myeloma Bone Disease	Suzanne Lentzsch
BCMA-specific ADC MEDI2228 and Daratumumab induce synergistic myeloma cytotoxicity via enhanced IFN-driven innate immune responses and expression of CD38 and NKG2D ligands	Yu-Tzu Tai
Monoallelic Deletion of BCMA Locus is a Frequent Feature in MM and is Associated with Increased Genomic Loss	Mehmet Samur

16:30-17:00	EXPOSITION AND BREAK
-------------	-----------------------------

17:00-18:00	INDUSTRY SYMPOSIUM SUPPORTED BY GSK
-------------	--

Welcome and Introduction	Mohamad Mohty (Chair)
Mechanism of action of anti-BCMA ADCs for the treatment of multiple myeloma	Katja Weisel
Positioning BCMA-targeted ADCs in the relapsed/refractory multiple myeloma setting	Suzanne Trudel
Management of adverse events caused by BCMA-targeted ADC therapy	Rakesh Popat
Panel discussion and concluding remarks	All faculty

18:00-19:00	POSTER SESSION
-------------	-----------------------

Friday, September 10th

08:00-09:00	MEET THE EXPERTS
-------------	-------------------------

Covid-19 and MM	Wenming Chen/ Sarah Holstein
Vaccination and prophylaxis in Myeloma	Laurent Garderet
Management of cellular therapy-related toxicities	Jesus Berdeja/Krina Patel
Bone disease control in Myeloma	Matthew Drake
Management of MM patients with renal impairment	Ruben Niesvizky

	Which is the ideal patient to be referred for CAR-T vs bispecific vs ADC?	Melissa Alsina/ Sham Mailankody
	Racial disparity and monoclonal gammopathies	Craig Cole
08:00-09:00	CAREER DEVELOPMENT WORKSHOP Developing your first clinical trial	Simon Harrison/ Jean-Luc Harousseau
09:00-09:30	OPENING SESSION Future of myeloma treatment	Jesus San Miguel
09:30-10:30	IMS/EHA SYMPOSIUM Immune Therapies: A game changer for Hematological Malignancies <i>Chairs: Kenneth Anderson/Pieter Sonneveld</i>	
	CART	TBC
	Other Immune Approaches	John Gribben
10:30-11:45	ORAL ABSTRACT SESSIONS <i>Session Chairs: Michael O'Dwyer</i>	
	Efficacy and safety of Ictacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with progressive multiple myeloma after 1–3 prior lines of therapy: Initial results from CARTITUDE-2	Adam Cohen
	Updated results from CARTITUDE-1: Ictacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T (CAR-T) cell therapy, in relapsed/refractory multiple myeloma (RRMM)	Sundar Jagannath
	Talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D)×CD3 bispecific antibody, in relapsed/refractory multiple myeloma (RRMM): Updated results of a phase 1, first-in-human study	Niels van de Donk
	MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM)	Bhagirathbhai Dholaria
	Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa	Larry Anderson
	<i>Session Chairs: Ruth De Tute/Aurore Perrot/Tomas Jelinek</i>	
	FAM46C-Dependent Tuning of Endoplasmic Reticulum Capacity in Multiple Myeloma	Enrico Milan
	Bone marrow adipocytes induce metabolic reprogramming of multiple myeloma cells	Cristina Panaroni
	Combined targeting of distinct c-Myc and JunB transcriptional programs induces synergistic anti-myeloma activity	Judith Lind

Circular RNA protein tyrosine kinase 2 promotes cell proliferation, migration and suppresses apoptosis via activating microRNA-638 mediated MEK/ERK, WNT/ β -catenin signaling pathways in myeloma	Fan Zhou
Targeting GSK in RAS-mutant multiple myeloma offer a promising therapeutic approach	Suzanne Lentzsch
Loss-of-function of GABARAP drives tumor resistance to bortezomib-induced immunogenic cell death in multiple myeloma	Annamaria Gulla

PLENARY SESSION

11:45-12:45

Other Plasma Cell Disorders

Session Chairs: Giampolo Merlini/Jorge Castillo

Current strategies for AL patients	Giovanni Palladini
What are the novel approaches in WM?	Steve Treon
Monoclonal gammopathy of clinical significance	Joan Blade
Monoclonal gammopathy of renal significance	Nelson Leung

12:45-13:45

EXPOSITION, POSTER SESSION AND LUNCH

13:45-15:15

INDUSTRY SYMPOSIUM SUPPORTED BY BMS

New Era of Immune Therapies in Multiple Myeloma

Welcome and introduction	Noopur Raje (Chair)
Cereblon E3 ligase as a therapeutic mediator for protein degradation	Nizar Bahlis
Early clinical data on cereblon E3 ligase modulators	Sagar Lonial
Clinical evidence for CAR T cell therapy in multiple myeloma	Nina Shah
The future of cellular and immune therapies in multiple myeloma	Noopur Raje
Discussion and Q&A	All faculty

15:15-16:30

ORAL ABSTRACT SESSIONS

Session Chairs: Jens Hillengass/Angelo Maiolino

Evaluating the Impact of Cytogenetic Abnormalities on Treatment Outcomes in Patients with AL Amyloidosis: Subanalyses From the ANDROMEDA Study	Shaji Kumar
Minimally invasive profiling of tumor and immune cells to stratify risk in smoldering multiple myeloma (SMM): the iMMunocell study	Rosalinda Termini
Graded Renal Response Criteria and Revised Renal Progression Criteria for Light chain (AL) Amyloidosis	Eli Muchtar
Assessing the prognostic utility of the Mayo 2018 and IMWG 2020 smoldering multiple myeloma risk stratification scores applied post diagnosis	Alyssa Visram
Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival	Eli Muchtar

Session Chairs: Constantine Mitsiades/Virgina Abello

Distinct immunoglobulin heavy-chain variable gene repertoire and its clinical relevance in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma	Yuting Yan
Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström Macroglobulinemia	Sabrin Tahri
Epithelial-mesenchymal-transition regulated by Junctional Adhesion Molecule-A (JAM-A) associates with aggressive extramedullary multiple myeloma disease.	Antonio Solimando
Targeting Free Light Chain Secretion via Botulinum Neurotoxin is a Novel Therapeutic Strategy in AL amyloidosis by Inducing a Terminal Unfolded Protein Response	Maria Moscvin
Progression and probability of progression are driven by different genomic features in precursor conditions in myeloma	Anil Aktas-Samur
Anti-CD38 nanobodies as theranostic agents for multiple myeloma	Elodie Duray

16:30-17:00

EXPOSITION AND BREAK

17:00-18:00

INDUSTRY SYMPOSIUM SUPPORTED BY AMGEN

Welcome and Introduction	Keith Stewart (Chair)
Defining Refractories in MM: The Scientific Perspective	Kwee Yong
Defining Refractories in MM: The clinical Perspective	Peter Voorhees
Optimal Treatment Sequencing for Managing MM in Early Relapse	Keith Stewart
Panel discussion and concluding remarks	All faculty

18:00-19:00

HOT TOPICS IN MYELOMA

Covid-19 in MM: what we have learnt?

Session Moderators: Karthik Ramasamy/Douglas Joshua

COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia	Andrew Branagan
COVID-19 infection in multiple myeloma patients – retrospective analysis of 371 Czech patients	Jakub Radocha
Plasma cell disorder patients are left vulnerable after one dose of the BNT162b2 mRNA or the ChAdOx-nCoV-19 COVID-19 vaccines	Wei Yee Chan
Suboptimal humoral immune response to SARS-CoV-2 mRNA vaccination in myeloma patients is associated with anti-CD38 mAb and BCMA-targeted treatment.	Oliver Van Oekelen
Poor Post-vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma correlates with low CD19+ B-lymphocyte count and Anti-CD38 Treatment	Susanne Ghandili

What have we learned?

Panelists: Joaquín Martínez, Pankaj Malhotra, Heinz Ludwig, Juan Du, Dorotea Fantl, Jakub Radocha

Evangelos Terpos

20:00-23:00

IMS CULTURAL CELEBRATION AND AWARDS PRESENTATION

Saturday, September 11, 2021

08:00-09:00

MEET THE EXPERTS

Animal models for myeloma

Karin Vanderkerkin/
Marta Chesi

Genomic techniques

Mark Bustoros/
Ruben Carrasco

Approaches to proteomic analysis

Saloman Manier/Naomi Puig

Primary sample processing and enrichment techniques

Jonathan Keats/Daniel Auclair

Single cell approaches

Manoj Bhasin/Jens Lohr

Assessing the immune system

Hearn Cho/Tax Kourelis

Metabolomics techniques in MM

Malathy Shanmugam/
Wilson Gonsalves

ChIP in Myeloma

Adam Sperling

08:00-09:00

CAREER DEVELOPMENT WORKSHOP

Setting up your laboratory research program

Rodger Tiedeman/
Larry Boise

09:00-10:00

INDUSTRY SYMPOSIUM SUPPORTED BY ONCOPEPTIDES

Welcome and Introduction

Graham Jackson (Chair)

Impact of patient and disease factors on choice to therapy in RRMM - how far have we come today?

Sikander Ailawadhi

Current treatment options in RRMM - which challenges remain?

Paula Rodriguez

What is coming on the horizon for RRMM - are the remaining challenges resolved?

Paul Richardson

Panel discussion and concluding remarks

All faculty

10:00-11:15

ORAL ABSTRACT SESSIONS

Session Chairs: Jae Hoon Lee/Elizabet Manasanach

OCEAN (OP-103): A Phase 3, Randomized, Global, Head-to-Head Comparison Study of Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)

Fredrik Schjesvold

Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Transplantation and MRD Response-Adapted Treatment Duration and Cessation in Newly Diagnosed Multiple Myeloma (NDMM)

Lu«ano J. Costa

Impact of chromosome 1 abnormalities on newly diagnosed multiple myeloma treated with proteasome inhibitor, immunomodulatory drug, and dexamethasone: analysis from the ENDURANCE ECOG-ACRIN E1A11 trial	Prashant Kapoor
Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-targeted CAR T therapy.	Oliver Van Oekelen
Single-cell RNA-sequencing identifies immune biomarkers of response to immunotherapy in patients with high-risk Smoldering Myeloma	Romanos Sklavenitis-Pistofidis
<i>Session Chairs: Mariateresa Fulciniti/Nicolo Bolli/Maria-Theresa Krauth</i>	
Gain and Amplification of 1q Induce Transcriptome Deregulation and Worsen the Outcome of Newly Diagnosed Multiple Myeloma Patients	Mattia D'Agostino
A machine learning model based on tumor and immune biomarkers to predict undetectable measurable residual disease (MRD) in transplant-eligible multiple myeloma (MM)	Camila Guerrero
Temporal-weight estimation of the copy number alterations of 1384 multiple myeloma patients defines an ancestrality index impacting patient survival	Andrea Poletti
Predictive relevance of sustained MRD negativity and of early loss of MRD negativity during maintenance therapy after transplant in newly diagnosed Multiple Myeloma patients	Angelo Belotti
Towards a comprehensive multimodal minimal residual disease assessment in multiple myeloma: the role of circulating cell-free DNA to define the extent of disease spreading	Marina Martello
Prospective comparison of contemporary whole body MRI and FDG PET/CT for disease detection and correlation with markers of disease burden in myeloma: Results of the iTIMM trial	Martin Kaiser

PLENARY SESSION

11:15-13:15

Great Debates in Myeloma

Moderators: Ludwig/Goldschmidt/Einsele/Hajek

Should every transplant eligible NDMM patient receive a transplant?	Sergio Giralto/Morie Gertz
Are we ready for MRD-guided therapy?	Sundar Jagannath/ Ola Landgren
Is stratification based on genomics ready for primetime?	Gareth Morgan/Faith Davies
Which is the best immune approach to replace ASCT?	Hermann Einsele/ Parameswaran Hari
Can we give our patient treatment free intervals?	Lu«ano Costa/ Phil McCarthy
Is there a role for alkylator in MM?	Donna Reece/Jeff Wolf

13:15-13:45

LUNCH

PLENARY SESSIONS

13:45-14:45

Supportive care management

Session Chairs: Andrezj Jakubowiak/Rafat Abonour

Management of renal failure	Jean-Paul Fermand
Approaches to bone health	Evangelos Terpos
Management of infections	Michel Delforge
Toxicity management	Elizabeth O'Donnell
Vaccinations in myeloma including covid-19	Heinz Ludwig

14:45-15:45

Immune Therapies

Session Chairs: Qing Yi/Ivan Borello

Mechanism of resistance to CAR-T cells and bispecifics	Yi Lin
How to improve the efficacy of CAR-T cells and bispecifics?	Michael Hudecek
Allo-CAR-T cells	Roman Hajek
CAR- NK cells	Adam Cohen
Vaccination Therapies for Myeloma	David Avigan

15:45-16:45

Clinical Trials in Progress

Moderators: William Bensinger/Raymond Comenzo

North America	Jonathan Kaufman
Europe	Xavier Leleu
South America	Vania Hungria
Asia	Jeffrey Huang
Australia	Hang Quach

16:45-16:55

WELCOME TO 19TH IMW

Organizers of 19th IMW

16:55-17:00

CLOSING COMMENTS

Organizers of 18th IMW

Ludwig/Goldschmidt/
Einsele/Hajek

The IMS gratefully acknowledges
the following organizations for
their sponsorship of the 18th
International Myeloma Workshop:

TITANIUM LEVEL



PHARMACEUTICAL COMPANIES OF *Johnson & Johnson*

PLATINUM LEVEL



SILVER LEVEL



ONCOLOGY